NEWARK, Calif.--(BUSINESS WIRE)--Vector Laboratories, the pioneer of innovative proteomic and glycomic research solutions, and Navinci Diagnostics, leader of innovative in situ proximity ligation ...

The new kit combines Vector’s validated lectins with Navinci’s in situ PLA technology to gain insights beyond protein expression The Glysite™ Explorer in situ PLA Glycan Detection Kit is a fully ...

GTCR, a leading private equity firm, today announced that it has completed a strategic equity investment in Vector Laboratories, Inc. (“Vector” or the “Company”), through GTCR’s previously established ...

Vector Laboratories, a manufacturing partner of reagents and critical components for the development and production of life sciences tools, diagnostics, and clinical-stage biotherapeutics, announced ...

If you’ve worked in a biomedical lab, there’s a good chance that you’ve used products from Vector Laboratories, pioneers in state-of-the-art labeling and detection technologies. Vector Laboratories ...

Over the last several decades, mounting interest has positioned bioconjugate therapeutics as one of the most promising biopharmaceutical modalities. Work in chemical biology, including novel ...

The collaboration between Vector Laboratories and Navinci Diagnostics will empower researchers’ ability to understand the glycosylation state of specific protein targets in the spatial context of ...

The new kit combines Vector's validated lectins with Navinci's in situ PLA technology to gain insights beyond protein expression Vector Laboratories, a leader in innovative proteomic and glycomic ...